Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan.
Understanding the Patterns of Serological Testing for COVID-19 Pre- and Post-Vaccination Rollout in Michigan.
复制标题
DOI：
10.3390/jcm10194341
复制
发表时间：
2021-09-24
影响因子：
3.9
通讯作者：
Fritsche LG
中科院分区：
文献类型：
--
作者：
Zhao Z;Salerno S;Shi X;Lee S;Mukherjee B;Fritsche LG
对SARS-CoV-2抗体的检测通常用于确定以前是否感染过新冠肺炎，并衡量感染或疫苗诱导的免疫水平。密歇根医学，一家主要的地区卫生中心，提供了一个理想的环境，以了解随着时间的推移血清学检测模式。在2020年4月27日至2021年5月3日期间，共收集了10,416名参加SARS-CoV-2抗体测试的个人的特征(共10,932项测试)。相对于新冠肺炎疫苗推出日期2020年12月14日，数据被分为疫苗推出前(8,026人)和疫苗推出后(2,587人)两个时期，并与未测试的个人进行对比，以确定与测试的个人和血清阳性相关的因素。对347名完全接种疫苗的人进行了疫苗介导的血清阳性反应的探索性分析。受试者的预测因素包括年龄、性别、吸烟、邻里变量和既往疾病。疫苗投放前血清阳性率为9.2%，疫苗投放后增至46.7%。在疫苗投放前阶段，血清阳性与年龄显著相关(10岁；OR=0.80(0.73，0.89)、是否吸烟(0.49(0.35，0.67))、呼吸系统疾病(4.38(3.13，6.12))、循环系统疾病(2.09(1.48，2.96))、肝病(2.06(1.11，3.84))、非西班牙裔黑人(2.18(1.33，3.58))和人口密度(1.10(1.03，1.18))。除后两者外，这些关联在疫苗投放后的时期仍具有统计学意义。全程接种者阳性率为296/347(85.3%，81.0%，88.8%)。
Testing for SARS-CoV-2 antibodies is commonly used to determine prior COVID-19 infections and to gauge levels of infection- or vaccine-induced immunity. Michigan Medicine, a primary regional health center, provided an ideal setting to understand serologic testing patterns over time. Between 27 April 2020 and 3 May 2021, characteristics for 10,416 individuals presenting for SARS-CoV-2 antibody tests (10,932 tests in total) were collected. Relative to the COVID-19 vaccine roll-out date, 14 December 2020, the data were split into a pre- (8026 individuals) and post-vaccine launch (2587 individuals) period and contrasted with untested individuals to identify factors associated with tested individuals and seropositivity. Exploratory analysis of vaccine-mediated seropositivity was performed in 347 fully vaccinated individuals. Predictors of tested individuals included age, sex, smoking, neighborhood variables, and pre-existing conditions. Seropositivity in the pre-vaccine launch period was 9.2% and increased to 46.7% in the post-vaccine launch period. In the pre-vaccine launch period, seropositivity was significantly associated with age (10 year; OR = 0.80 (0.73, 0.89)), ever-smoker status (0.49 (0.35, 0.67)), respiratory disease (4.38 (3.13, 6.12)), circulatory disease (2.09 (1.48, 2.96)), liver disease (2.06 (1.11, 3.84)), non-Hispanic Black race/ethnicity (2.18 (1.33, 3.58)), and population density (1.10 (1.03, 1.18)). Except for the latter two, these associations remained statistically significant in the post-vaccine launch period. The positivity rate of fully vaccinated individual was 296/347(85.3% (81.0%, 88.8%)).
登录
查看更多内容
影响因子：
--
作者：
An J;Liao X;Xiao T;Qian S;Yuan J;Ye H;Qi F;Shen C;Wang L;Liu Y;Cheng X;Li N;Cai Q;Wang F;Chen J;Li G;Cai Q;Liu Y;Wang Y;Zhang F;Fu Y;He Q;Tan X;Liu L;Zhang Z
通讯作者：
Zhang Z
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
13.6
作者：
Clarke, Candice;Prendecki, Maria;Willicombe, Michelle
通讯作者：
Willicombe, Michelle
影响因子：
11.7
作者：
Lau, H.;Khosrawipour, T.;Khosrawipour, V
通讯作者：
Khosrawipour, V
影响因子：
8.8
作者：
de Oliveira ACS;Morita LHM;da Silva EB;Zardo LAR;Fontes CJF;Granzotto DCT
通讯作者：
Granzotto DCT